Roquette
, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, welcomes
CPHI
Milan attendees to explore the synergistic potential of its
expanded
excipients portfolio, a
year
after
the
acquisition
of leading capsule manufacturer,
Qualicaps
. At the event,
Roquette
will showcase its new strategic direction through cutting-edge insights, samples and product demonstrations, all of which highlight how together,
Roquette
and
Qualicaps
unlock healthier futures. In addition, the company will reveal its latest breakthrough PEARLITOL® 200 INH mannitol, a carrier specifically developed for dry powder inhalers (DPI). Designed to optimize the performance of DPI formulations when harnessed alongside purpose-built
Qualicaps
capsules, this high-performance excipient provides a tangible example of inter-company synergy and its potential to improve patient care.
Surveying the synergies
Twelve months on from the announcement at
CPHI
2023,
Roquette
’s
acquisition
of
Qualicaps
has solidified its position as a leading, end-to-end solutions provider for oral dosage forms. Both companies hold strong positions in their respective markets and stand at the forefront of innovation, universally recognized as top-tier global players. Now, their blended expertise allows
Roquette
to offer everything from fillers, binders, encapsulants, disintegrants, lubricants and more, as well as the high-quality capsules that house the final product. What’s more, the combination of the companies’ manufacturing assets, supply chain, in-depth customer knowledge and commercial and technical
capabilities
provide drug producers with a solid, unified foundation for exceptional service quality, wherever they are based.
“It’s incredible to see the impact the
acquisition
has had in just 12 short months, particularly in terms of knowledge sharing and the exploration of complementary synergies between our companies,” comments Paul Smaltz, Vice President of Pharmaceutical Solutions at
Roquette
. “Looking to the future, we’ll continue our review of the
Roquette
and
Qualicaps
portfolios, searching for new combined solutions to help our customers unlock brighter, better, more innovative treatments for patients.”
PEARLITOL® 200 INH: Optimized for inhalation
Visitors to the
Roquette
and
Qualicaps
booth are invited to witness the combined power of the
expanded
portfolio through the companies’ latest innovation PEARLITOL® 200 INH, a mannitol carrier for dry powder inhalers (DPI).
Roquette
’s first dedicated solution for inhalation routes of administration, this highly refined mannitol exhibits optimal particle size distribution (PSD) for DPIs, optimizing production efficiency. Like all
Roquette
excipient solutions, PEARLITOL® 200 INH is inherently safe and compliant with major international pharmacopeia, while its low reducing sugars and non-hygroscopic properties make it suitable for use with a wide array of active pharmaceutical ingredients – even those with high moisture sensitivity. This versatility alongside precise functionality unlocks powerful synergies when paired with
Qualicaps
’ best-in-class Quali-V®-I plant-based capsules for dry powder inhalers. The optimized powder properties of PEARLITOL® 200 INH combined with precisely engineered capsules designed for superior puncturing, emptying and aerosolization, results in a solution with outstanding performance, supporting the highest standards in inhalation therapy.
Join the experts at booth 6A58 to learn more about this latest launch and explore the
expanded
potential of the
Roquette
and
Qualicaps
portfolio.
content
See Full Bio
